Corcept Therapeutics

OverviewSuggest Edit

Corcept Therapeutics is a pharmaceutical company which discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome. The Company is also developing Korlym in different combinations to treat patients with triple-negative breast cancer and metastatic castration-resistant prostate cancer. In addition, it develops product candidates for the treatment of Cushing's syndrome and solid-tumor cancers.

TypePublic
Founded1998
HQMenlo Park, US
Websitecorcept.com
Employee Ratings3.8

Latest Updates

Employees (est.) (Dec 2018)166(+23%)
Job Openings11
Revenue (FY, 2016)$81.3 M(+62%)
Share Price (Jun 2019)$10.1

Key People/Management at Corcept Therapeutics

Joseph K. Belanoff

Joseph K. Belanoff

MD, Chief Executive Officer, President and Director
Robert S. Fishman

Robert S. Fishman

MD, Chief Medical Officer
Hazel Hunt

Hazel Hunt

PhD, Senior Vice President, Research
Sean Maduck

Sean Maduck

Senior Vice President, Commercial
Charles Robb

Charles Robb

CFO
Show more

Corcept Therapeutics Office Locations

Corcept Therapeutics has an office in Menlo Park
Menlo Park, US (HQ)
149 Commonwealth Dr
Show all (1)

Corcept Therapeutics Financials and Metrics

Corcept Therapeutics Revenue

Corcept Therapeutics's revenue was reported to be $81.32 m in FY, 2016 which is a 61.7% increase from the previous period.
USD

Net income (Q2, 2019)

20.2m

EBIT (Q2, 2019)

24.6m

Market capitalization (10-Jun-2019)

1.2b

Closing stock price (10-Jun-2019)

10.1

Cash (30-Jun-2019)

58.1m
Corcept Therapeutics's current market capitalization is $1.2 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

10.4m26.6m50.3m81.3m

Revenue growth, %

156%89%62%

Cost of goods sold

143.0k882.0k1.4m2.1m3.6m5.2m

Gross profit

10.2m25.7m48.9m79.3m
Quarterly
USDQ3, 2013Q3, 2014Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Revenue

2.6m7.3m

Cost of goods sold

40.0k235.0k646.0k775.0m976.0k1.2m1.2m1.3m1.2m1.4m

Gross profit

2.6m7.0m

Gross profit Margin, %

98%97%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

54.9m24.2m40.4m51.5m31.1m41.6m

Accounts Receivable

Inventories

1.1m1.4m1.7m2.3m4.6m4.7m

Current Assets

58.3m30.2m49.0m65.7m124.2m236.8m
Quarterly
USDQ3, 2013Q3, 2014Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Cash

63.2m26.8m47.9m38.0m33.6m31.1m33.1m31.2m33.9m49.7m58.1m

Accounts Receivable

1.0m

Inventories

1.0m1.1m2.3m2.9m3.1m3.8m4.9m4.9m5.4m5.0m5.1m

Current Assets

66.2m32.4m59.8m66.7m81.3m93.9m150.8m197.2m224.2m216.9m232.7m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(46.0m)(31.4m)(6.4m)8.1m129.1m75.4m

Inventories

(883.0k)(531.0k)815.0k(682.0k)(2.3m)(7.8m)

Accounts Payable

(1.4m)(495.0k)(561.0k)965.0k6.3m(389.0k)

Cash From Operating Activities

(37.1m)(27.4m)3.1m18.4m60.9m115.7m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Net Income

30.8m17.5m35.7m53.4m18.3m38.5m

Inventories

1.0m1.1m1.1m1.1m1.3m1.5m1.6m1.9m2.1m2.3m2.9m(344.0k)590.0k(2.1m)(4.3m)910.0k(1.5m)

Accounts Payable

2.3m3.7m2.6m2.0m1.0m2.4m1.7m2.1m2.1m4.3m4.3m3.9m(759.0k)(2.2m)5.3m953.0k(1.3m)

Cash From Operating Activities

36.1m34.4m49.6m94.1m23.7m49.2m
USDY, 2019

Financial Leverage

1.1 x
Show all financial metrics

Corcept Therapeutics Online and Social Media Presence

Embed Graph

Corcept Therapeutics News and Updates

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Corcept Therapeutics Incorporated To Contact The Firm

NEW YORK, April 11, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Corcept Therapeutics Incorporated ("Corcept" or the "Company")(NASDAQ: CORT) of the May 13, 2019 deadline to seek the role of lead plaintiff in a federal securities...

Hagens Berman Reminds Corcept Therapeutics (CORT) Investors of May 13, 2019 Lead Plaintiff Deadline

San Francisco - Hagens Berman Sobol Shapiro LLP reminds investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) of the May 13, 2019 Lead Plaintiff deadline in the pending securities class action.  If you purchased or otherwise acquired Corcept Therapeutics securities between August 2, 2017 and…

CORT Class Action Alert: Hagens Berman Alerts Corcept Therapeutics (NASDAQ: CORT) Investors to Securities Class Action and May 13, 2019 Lead Plaintiff Deadline

SAN FRANCISCO, March 19, 2019 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) to the May 13, 2019 Lead Plaintiff deadline in the securities class action pending in the United States District Court for the Northern...

Corcept Therapeutics Appoints Former Amgen Development Executive, Andreas Grauer, M.D., as Chief Medical Officer

MENLO PARK, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone corti…

Corcept Therapeutics Announces fourth quarter and full-year 2018 Audited Financial Results and provides corporate update

MENLO PARK, Calif., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone corti…

Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Investigation of Possible Accounting Irregularities and Securities Law Violations

SAN FRANCISCO, Feb. 7, 2019 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) of the Firm's investigation of possible violations of the Federal securities laws. If you purchased or otherwise acquired Corcept Therapeutics...
Show more

Corcept Therapeutics Blogs

Corcept Therapeutics Announces Second Quarter 2019 Financial Results and Provides Corporate Update

Corcept Therapeutics Announces Second Quarter 2019 Financial Results and Provides Corporate Update Content Import Thu, 08/01/2019 - 16:06 Corcept Therapeutics Announces Second Quarter 2019 Financial Results and Provides Corporate Update August 1, 2019 at 4:05 PM EDT …

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

MENLO PARK, Calif. , July 25, 2019 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on August 1, 2019 . The company will also host a conference call that day at 5:00 p.m.

Corcept Therapeutics Frequently Asked Questions

  • When was Corcept Therapeutics founded?

    Corcept Therapeutics was founded in 1998.

  • Who are Corcept Therapeutics key executives?

    Corcept Therapeutics's key executives are Joseph K. Belanoff, Robert S. Fishman and Hazel Hunt.

  • How many employees does Corcept Therapeutics have?

    Corcept Therapeutics has 166 employees.

  • Who are Corcept Therapeutics competitors?

    Competitors of Corcept Therapeutics include Insys Therapeutics, ASLAN Pharmaceuticals and Shanghai Henlius Biotech.

  • Where is Corcept Therapeutics headquarters?

    Corcept Therapeutics headquarters is located at 149 Commonwealth Dr, Menlo Park.

  • Where are Corcept Therapeutics offices?

    Corcept Therapeutics has an office in Menlo Park.

  • How many offices does Corcept Therapeutics have?

    Corcept Therapeutics has 1 office.